The Use of MR Imaging as an Outcome Measure in Multiple Sclerosis Clinical Trials

Neuroimaging Clinics of North America

Volumn 18, Issue 4, 2008, Pages 687-701

  Bermel, Robert A ^a   Fisher, Elizabeth ^a   Cohen, Jeffrey A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Clinical trials; Magnetic resonance imaging; Multiple sclerosis; Outcomes

Indexed keywords

GADOLINIUM;

BLOOD BRAIN BARRIER; BRAIN ATROPHY; BRAIN DAMAGE; CENTRAL NERVOUS SYSTEM; COMPUTER PROGRAM; DEMYELINATION; DIFFUSION TENSOR IMAGING; DISEASE ACTIVITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INFLAMMATION; MAGNETISM; MULTIPLE SCLEROSIS; NERVE CELL PLASTICITY; NERVE FIBER; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SPINAL CORD ATROPHY;

ATROPHY; BRAIN; CLINICAL TRIALS AS TOPIC; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS;

EID: 54949142855     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nic.2008.06.008     Document Type: Review

References (105)

1. Lublin F.D., and Reingold S.C. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Ann Neurol 49 5 (2001) 677-681
2. Cohen J.A., and Rudick R.A. Aspects of multiple sclerosis that relate to trial design and clinical management. In: Cohen J.A., and Rudick R.A. (Eds). Multiple sclerosis therapeutics. 3rd edition (2007), Informa Healthcare, London 3-22
3. Sormani M.P., Rovaris M., Bagnato F., et al. Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments. Neurology 57 10 (2001) 1883-1885
4. Paty D.W., Li D.K., Oger J.J., et al. Magnetic resonance imaging in the evaluation of clinical trials in multiple sclerosis. Ann Neurol 36 Suppl (1994) S95-S96
5. Martinelli Boneschi F., Rovaris M., Comi G., et al. The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials. Multiple Sclerosis 10 4 (2004) 341-347
6. Prentice R.L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8 4 (1989) 431-440
7. Smith M.E., Stone L.A., Albert P.S., et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 33 5 (1993) 480-489
8. Filippi M., Rovaris M., Capra R., et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain 121 Pt 10 (1998) 2011-2020
9. Silver N.C., Good C.D., Sormani M.P., et al. A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis. J Neurol 248 3 (2001) 215-224
10. Molyneux P.D., Filippi M., Barkhof F., et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 43 3 (1998) 332-339
11. Stone L.A., Albert P.S., Smith M.E., et al. Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology 45 10 (1995) 1808-1814
12. Simon J.H., and Miller D.E. Measures of gadolinium enhancement, T1 black holes and T2-hyperintense lesions on magnetic resonance imaging. In: Cohen J.A., and Rudick R.A. (Eds). Multiple sclerosis therapeutics. 3rd edition (2007), Informa Healthcare, London 113-142
13. Li D.K., and Paty D.W. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol 46 2 (1999) 197-206
14. Rudick R.A., Lee J.C., Simon J., et al. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol 60 2 (2006) 236-242
15. Bakshi R., Ariyaratana S., Benedict R.H., et al. Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions. Arch Neurol 58 5 (2001) 742-748
16. Filippi M., Rocca M.A., Gasperini C., et al. Interscanner variation in brain MR lesion load measurements in multiple sclerosis using conventional spin-echo, rapid relaxation-enhanced, and fast-FLAIR sequences. AJNR Am J Neuroradiol 20 1 (1999) 133-137
17. Sanfilipo M.P., Benedict R.H., Sharma J., et al. The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. Neuroimage 26 4 (2005) 1068-1077
18. van Walderveen M.A., Kamphorst W., Scheltens P., et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 50 5 (1998) 1282-1288
19. Simon J.H., Lull J., Jacobs L.D., et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group. Neurology 55 2 (2000) 185-192
20. Bermel R.A., Sharma J., Tjoa C.W., et al. A semiautomated measure of whole-brain atrophy in multiple sclerosis. J Neurol Sci 208 1-2 (2003) 57-65
21. Paolillo A., Pozzilli C., Gasperini C., et al. Brain atrophy in relapsing-remitting multiple sclerosis: relationship with 'black holes,' disease duration and clinical disability. J Neurol Sci 174 2 (2000) 85-91
22. Rudick R.A., Fisher E., Lee J.C., et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53 8 (1999) 1698-1704
23. Miller D.H., Barkhof F., Frank J.A., et al. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125 Pt 8 (2002) 1676-1695
24. Bermel R.A., and Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 5 2 (2006) 158-170
25. Paolillo A., Piattella M.C., Pantano P., et al. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA. J Neurol 251 4 (2004) 432-439
26. Brex P.A., Jenkins R., Fox N.C., et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 54 8 (2000) 1689-1691
27. Fisher E., Rudick R.A., Cutter G., et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 6 6 (2000) 373-377
28. Pelletier D., Garrison K., and Henry R. Measurement of whole-brain atrophy in multiple sclerosis. [Review] [53 refs]. J Neuroimaging 14 3 Suppl (2004) 11S-9S
29. Simon J.H. Linear and regional measures of brain atrophy in multiple sclerosis. In: Zivadinov R., and Bakshi R. (Eds) (2004), Nova Science, Hauppauge (NY) 15-27
30. Ge Y., Grossman R.I., Udupa J.K., et al. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology 214 3 (2000) 665-670
31. Smith S.M., Zhang Y., Jenkinson M., et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17 1 (2002) 479-489
32. Collins D.L., Montagnat J., Zijdenbos A.P., et al. Automated estimation of brain volume in multiple sclerosis with BICCR. Lect Notes Comput Sci 2082 (2001) 141-147
33. Fox N.C., Jenkins R., Leary S.M., et al. Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology 54 4 (2000) 807-812
34. Smith S.M., De Stefano N., Jenkinson M., et al. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 25 3 (2001) 466-475
35. Chard D.T., Parker G.J., Griffin C.M., et al. The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology. J Magn Reson Imaging 15 3 (2002) 259-267
36. Anderson V.M., Bartlett J.W., Fox N.C., et al. Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates. J Neurol 254 11 (2007) 1588-1594
37. Zivadinov R., Grop A., Sharma J., et al. Reproducibility and accuracy of quantitative magnetic resonance imaging techniques of whole-brain atrophy measurement in multiple sclerosis. J Neuroimaging 15 1 (2005) 27-36
38. Jones C.K., Riddehough A., Li D.K.B., et al. MRI cerebral atrophy in relapsing-remitting MS: results from the PRISMS trial. Neurology 56 Suppl 3 (2001) A379 [abstract]
39. Filippi M., Rovaris M., Inglese M., et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 364 9444 (2004) 1489-1496
40. Fox R.J., Fisher E., Tkach J., et al. Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications. Mult Scler 11 2 (2005) 140-145
41. Kappos L., Moeri D., Radue E.W., et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 353 9157 (1999) 964-969
42. Sormani M.P., Bruzzi P., Beckmann K., et al. MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b. Neurology 60 9 (2003) 1462-1466
43. Paolillo A., Coles A.J., Molyneux P.D., et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53 4 (1999) 751-757
44. Rice G.P., Filippi M., and Comi G. Cladribine and progressive: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 54 5 (2000) 1145-1155
45. Filippi M., McGowan J.C., and Tortorella C. Measures of magnetization transfer in multiple sclerosis. In: Cohen J.A., and Rudick R.A. (Eds). Multiple sclerosis therapeutics. 3rd edition (2007), Informa Healthcare, London 143-171
46. van Waesberghe J.H., Kamphorst W., De Groot C.J., et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 46 5 (1999) 747-754
47. Phillips M.D., Grossman R.I., Miki Y., et al. Comparison of T2 lesion volume and magnetization transfer ratio histogram analysis and of atrophy and measures of lesion burden in patients with multiple sclerosis. AJNR Am J Neuroradiol 19 6 (1998) 1055-1060
48. Cercignani M., Iannucci G., Rocca M.A., et al. Pathologic damage in MS assessed by diffusion-weighted and magnetization transfer MRI. Neurology 54 5 (2000) 1139-1144
49. Filippi M., Iannucci G., Tortorella C., et al. Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology 52 3 (1999) 588-594
50. Kalkers N.F., Hintzen R.Q., van Waesberghe J.H., et al. Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy. J Neurol Sci 184 2 (2001) 155-162
51. Inglese M., van Waesberghe J.H., Rovaris M., et al. The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. Neurology 60 5 (2003) 853-860
52. van Waesberghe J.H., van Walderveen M.A., Castelijns J.A., et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 19 4 (1998) 675-683
53. Richert N.D., Ostuni J.L., Bash C.N., et al. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler 7 1 (2001) 49-58
54. Kita M., Goodkin D.E., Bacchetti P., et al. Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a. Neurology 54 9 (2000) 1741-1745
55. Horsfield M.A., Barker G.J., Barkhof F., et al. Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis. J Magn Reson Imaging 17 4 (2003) 389-397
56. Rocca M.A., Cercignani M., Iannucci G., et al. Weekly diffusion-weighted imaging of normal-appearing white matter in MS. Neurology 55 6 (2000) 882-884
57. Werring D.J., Brassat D., Droogan A.G., et al. The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain 123 Pt 8 (2000) 1667-1676
58. Cassol E., Ranjeva J.P., Ibarrola D., et al. Diffusion tensor imaging in multiple sclerosis: a tool for monitoring changes in normal-appearing white matter. Mult Scler 10 2 (2004) 188-196
59. Fox R.J., Sakaie K., Lee J.C., et al. A validation study of multi-centre diffusion tensor imaging. Mult Scler 13 Suppl 7 (2007) S76
60. Bjartmar C., Battistuta J., Terada N., et al. N-acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve. Ann Neurol 51 1 (2002) 51-58
61. Matthews P.M., Pioro E., Narayanan S., et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 119 Pt 3 (1996) 715-722
62. Fu L., Matthews P.M., De Stefano N., et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 121 Pt 1 (1998) 103-113
63. Khan O., Shen Y., Caon C., et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 11 6 (2005) 646-651
64. Sarchielli P., Presciutti O., Tarducci R., et al. 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatry 64 2 (1998) 204-212
65. Parry A., Corkill R., Blamire A.M., et al. Beta-interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol 250 2 (2003) 171-178
66. Inglese M., Ge Y., Filippi M., et al. Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis. Neuroimage 21 4 (2004) 1825-1829
67. Rovaris M., Gambini A., Gallo A., et al. Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. Neurology 65 10 (2005) 1626-1630
68. De Stefano N., Filippi M., Miller D., et al. Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology 69 20 (2007) 1942-1952
69. Simon J.H. Brain and spinal cord atrophy in multiple sclerosis. Neuroimaging Clin N Am 10 4 (2000) 753-70
70. Stevenson V.L., Leary S.M., Losseff N.A., et al. Spinal cord atrophy and disability in MS: a longitudinal study. Neurology 51 1 (1998) 234-238
71. Sailer M., Fischl B., Salat D., et al. Focal thinning of the cerebral cortex in multiple sclerosis. Brain 126 Pt 8 (2003) 1734-1744 [see comment]
72. De Stefano N., Matthews P.M., Filippi M., et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 60 7 (2003) 1157-1162
73. Tiberio M., Chard D.T., Altmann D.R., et al. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology 64 6 (2005) 1001-1007
74. Sastre-Garriga J., Ingle G.T., Chard D.T., et al. Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. Neuroimage 22 1 (2004) 353-359
75. Sanfilipo M.P., Benedict R.H., Weinstock-Guttman B., et al. Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology 66 5 (2006) 685-692
76. Benedict R.H., Zivadinov R., Carone D.A., et al. Regional lobar atrophy predicts memory impairment in multiple sclerosis. AJNR Am J Neuroradiol 26 7 (2005) 1824-1831
77. Filippi M., Rocca M.A., Colombo B., et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage 15 3 (2002) 559-567
78. Polman C.H., Reingold S.C., Edan G., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria.". Ann Neurol 58 6 (2005) 840-846
79. Martinez-Yelamos S., Martinez-Yelamos A., Martin Ozaeta G., et al. Regression to the mean in multiple sclerosis. Mult Scler 12 6 (2006) 826-829
80. Katz D., Taubenberger J.K., Cannella B., et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 34 5 (1993) 661-669
81. Panitch H.S., Hirsch R.L., Schindler J., et al. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 37 7 (1987) 1097-1102
82. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53 3 (1999) 457-465
83. Bielekova B., Goodwin B., Richert N., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6 10 (2000) 1167-1175
84. Chen J.T., Collins D.L., Atkins H.L., et al. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 66 12 (2006) 1935-1937
85. Langer-Gould A., Atlas S.W., Green A.J., et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353 4 (2005) 375-381
86. Kappos L., Antel J., Comi G., et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355 11 (2006) 1124-1140
87. Tubridy N., Behan P.O., Capildeo R., et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 53 3 (1999) 466-472
88. Bielekova B., Richert N., Howard T., et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A 101 23 (2004) 8705-8708
89. O'Connor P., Miller D., Riester K., et al. Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. Mult Scler 11 5 (2005) 568-572
90. Polman C.H., O'Connor P.W., Havrdova E., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 9 (2006) 899-910
91. Rudick R.A., Stuart W.H., Calabresi P.A., et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354 9 (2006) 911-923
92. Sormani M.P., Molyneux P.D., Gasperini C., et al. Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results. J Neurol Neurosurg Psychiatry 66 4 (1999) 465-469
93. Filippi M., Yousry T., Campi A., et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology 46 2 (1996) 379-384
94. Gasperini C., Pozzilli C., Bastianello S., et al. The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: a longitudinal MRI study in relapsing-remitting multiple sclerosis patients. Acta Neurol Scand 95 4 (1997) 201-207
95. Goodin D.S. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?. Ann Neurol 59 4 (2006) 597-605
96. Filippi M., Rocca M.A., and Comi G. The use of quantitative magnetic-resonance-based techniques to monitor the evolution of multiple sclerosis. Lancet Neurol 2 6 (2003) 337-346
97. Molyneux P.D., Miller D.H., Filippi M., et al. The use of magnetic resonance imaging in multiple sclerosis treatment trials: power calculations for annual lesion load measurement. J Neurol 247 1 (2000) 34-40
98. Han X., Jovicich J., Salat D., et al. Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer. Neuroimage 32 1 (2006) 180-194
99. Gasperini C., Rovaris M., Sormani M.P., et al. Intra-observer, inter-observer and inter-scanner variations in brain MRI volume measurements in multiple sclerosis. Mult Scler 7 1 (2001) 27-31
100. Molyneux P.D., Wang L., Lai M., et al. Quantitative techniques for lesion load measurement in multiple sclerosis: an assessment of the global threshold technique after non uniformity and histogram matching corrections. Eur J Neurol 5 1 (1998) 55-60
101. Raff U., Rojas G.M., Hutchinson M., et al. Quantitation of T2 lesion load in patients with multiple sclerosis: a novel semiautomated segmentation technique. Acad Radiol 7 4 (2000) 237-247
102. Alfano B., Brunetti A., Larobina M., et al. Automated segmentation and measurement of global white matter lesion volume in patients with multiple sclerosis. J Magn Reson Imaging 12 6 (2000) 799-807
103. Anbeek P., Vincken K.L., van Osch M.J., et al. Automatic segmentation of different-sized white matter lesions by voxel probability estimation. Med Image Anal 8 3 (2004) 205-215
104. Wu Y., Warfield S.K., Tan I.L., et al. Automated segmentation of multiple sclerosis lesion subtypes with multichannel MRI. Neuroimage 32 3 (2006) 1205-1215
105. Achiron A., Gicquel S., Miron S., et al. Brain MRI lesion load quantification in multiple sclerosis: a comparison between automated multispectral and semi-automated thresholding computer-assisted techniques. Magn Reson Imaging 20 10 (2002) 713-720